Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study-Reference-Cited by-同舟云学术

Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Published:2021-06-20 Issue:3 Volume:54 Page:292-301
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Ko Yanna¹²^ORCID,Paramsothy Sudarshan¹²³^ORCID,Yau Yunki¹,Leong Rupert W.¹²³^ORCID

Affiliation:

1. Gastroenterology and Liver Services Concord Repatriation General Hospital Sydney NSW Australia

2. Concord Clinical School The University of Sydney Sydney NSW Australia

3. Faculty of Medicine and Health Sciences Macquarie University Sydney NSW Australia

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16436

Reference31 articles.

1. Big data in IBD: a look into the future

2. Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn's disease and ulcerative colitis

3. Biologic agents for IBD: practical insights

4. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

5. Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study;BMC Gastroenterology;2024-09-11

2. Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn’s Disease and Fistula Initiated on Ustekinumab;Advances in Therapy;2024-08-20

3. Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases–an observational study;PLOS ONE;2024-06-13

4. Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review;Microbiological Research;2024-05

5. Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial;Clinical Gastroenterology and Hepatology;2024-05